Vanguard Group Inc Lantern Pharma Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 363,720 shares of LTRN stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
363,720
Previous 363,720
-0.0%
Holding current value
$1.17 Million
Previous $1.16 Million
11.33%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LTRN
# of Institutions
35Shares Held
2.41MCall Options Held
17.1KPut Options Held
1.3K-
Bios Capital Management, LP Fort Worth, TX1.21MShares$3.9 Million5.4% of portfolio
-
Cm Management, LLC200KShares$646,0000.77% of portfolio
-
Geode Capital Management, LLC Boston, MA90.5KShares$292,3270.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny88.8KShares$286,8240.0% of portfolio
-
New Edge Advisors, LLC New Orleans, LA59.9KShares$193,5540.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $35M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...